Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2
- 31 August 1991
- journal article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 27 (8) , 1014-1016
- https://doi.org/10.1016/0277-5379(91)90271-e
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancer.Journal of Clinical Oncology, 1989
- Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens.Journal of Clinical Oncology, 1988
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- An analysis of the cellular requirements for the production of soluble interleukin-2 receptorsin vitroJournal of Clinical Immunology, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.The Journal of Experimental Medicine, 1984
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- Suppressor Cells in Neoplastic DiseaseJNCI Journal of the National Cancer Institute, 1978
- Suppression of cell-mediated tumour immunity by Corynebacterium parvumNature, 1975
- EVIDENCE OF SUPPRESSOR CELL ACTIVITY IN SPLEENS OF MICE BEARING PRIMARY TUMORS INDUCED BY MOLONEY SARCOMA VIRUSThe Journal of Experimental Medicine, 1974